Nasdaq(NDAQ) Prnewswire·2025-02-14 22:15Core Points - Oncolytics Biotech Inc. received a delinquency notification from Nasdaq due to its ordinary shares closing below $1.00 for 30 consecutive business days, which is a violation of Nasdaq's minimum bid price requirement [1][2] - The company has until August 12, 2025, to regain compliance with the minimum bid price requirement, during which its shares will continue to trade on Nasdaq [2][3] - If the company fails to regain compliance by the deadline, it may be eligible for additional time to meet the listing requirements, provided it meets other criteria [3] Company Overview - Oncolytics Biotech Inc. is a clinical-stage biotechnology company focused on developing pelareorep, an immunotherapeutic agent for cancer treatment [4] - Pelareorep has shown promising results in clinical studies for metastatic breast cancer and pancreatic cancer, and it works by inducing anti-cancer immune responses [4][5] - The company is conducting combination clinical trials with pelareorep and has received Fast Track designation from the FDA for its studies in metastatic breast cancer and pancreatic cancer [5]